image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 9 days, don't miss out!

Vistry

December 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • VTY
  • Price:
  • 745p
The months of September and October have seen a chillier wind blowing through the new build housing market as higher interest rates start to bite and even though Vistry has reduced its reliance on private new build sales in favour of social housing and build to rent, it’s not immune. Its Q3 update said it now expects £450m pretax profit for the year versus previously expecting to exceed that number. Vistry also flagged £40m one off costs from the reorganisation to a single Partnerships division and some extra interest costs. As a result, Peel Hunt has downgraded pretax profit forecasts to £406m for 84.4p. For next year and FY25 they rise to £430m and £545m for eps of 89.9p and 117.8p, respectively. Its target price is 1300p. V ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author